The study seeks to assess the safety and define blood and tissue benchmark concentrations of
Tenofovir (TFV) and Tenofovir diphosphate (TFV-DP) in Cisgender women using directly observed
tenofovir alafenamide (TAF)-emtricitabine (TAF-FTC) pre-exposure prophylaxis (PrEP). These
data will help accurate interpretation of efficacy results obtained in HIV prevention trials
and programs in cisgender women.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Washington
Collaborators:
Gilead Sciences Kenya Medical Research Institute University of Colorado, Denver